Research
Hormonal
GLP-1 based medications can achieve an average weight loss of 24%.
Practitioners can expect significant weight loss with GLP-1 medications.
StrongSupportsmedium confidence
Estos nuevos fármacos llegan a alcanzar valores medios de pérdida de peso del 24%.
Why this rating
The claim is based on the results of new antiobesity medications.
Source
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Javier Salvador · Medicina Clínica · 2025
DOI 10.1016/j.medcli.2025.107035
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →